Phase 2 N=90 Open Label Extension Study of AMX0035 in Patients With ALS
Amyotrophic Lateral Sclerosis · ALS
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 81 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 An Exposure-Based Implementation Strategy to Decrease Clinician Anxiety Around Suicide Prevention
Implementation Science
Primary: Clinician Perception of EBIS Acceptability for Clinical Practice at Time 4, 12 Weeks After Completing Training — 4.55; 4.56 units on a scale — p=.47
N/A N=12 Effect of Telehealth Mindfulness on Sleep and Anxiety in Acquired Brain Injury Population
Acquired Brain Injury
Primary: Pittsburgh Sleep Quality Index (PSQI) — 7.73; 4.00 units on a scale — p=0.00058
N/A N=35 Low Nicotine Cigarettes, Smoking, and Chronic Pain
Chronic Pain · Smoking, Cigarette
Primary: Cigarettes Smoked Per Day — 14.5; 17.2; 16.4; 20.3 cigarettes/day — p=<.0001
N/A N=122 Exercise Effects on Brain Health and Learning From Minutes to Months
Sedentary Lifestyle
Primary: Change in Hippocampal-dependent Learning — -.00369; .00404 learning rate (proportion correct/trial) — p=<.05
N/A N=96 Cognitive Behavioral Couple Therapy for Perinatal Distress
Perinatal Depression · Perinatal Anxiety
Primary: The Sum of Scores of Major Depressive Disorder Subscale and Generalized Anxiety Disorder Subscale — 18.14; 17.31; 15.62; 8.62 score on a scale — p=0.000
N/A N=71 Molecular Pathways Involved in Knee Pain
Knee Osteoarthritis · Knee Pain Chronic
Primary: Pain Sensitivity: Pressure Pain Detection Threshold (PPT) — 252.58; 266.17 kPa
N/A N=64 Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain
Neuropathy, Diabetic · Neuropathy;Peripheral · Neuropathy, Painful
Primary: Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS) — 24; 9 participants
Phase 3 N=275 A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
Dry Eye Disease
Primary: Ocular Treatment-Emergent Adverse Events by Preferred Term With Incidence Greater Than 2 Percent — 90; 7; 2; 3 adverse event
N/A N=66 Physiologic Phacofluidics: Ghost Protocol
Cataract
Primary: Change in Early Post Operative Central Corneal Thickness — 623.9; 650.2 microns
Phase 1 N=29 A Study of LY3039478 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Mean Time-Matched Difference in Placebo-Adjusted QTcF Interval With Time Matched Concentrations Between LY3039478 Capsule Formulation (Formulation…
N/A N=124 The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
MDD
Primary: Mean Change in Depressive Symptoms, Measured by HDRS17 Total Score — -8.62; -6.01 units on a scale
N/A N=121 A Transdiagnostic Sleep and Circadian Treatment to Improve Community SMI Outcomes
Mental Disorders
Primary: Impairment (Sheehan Disability Scale) — 14.30; 12.03; 11.76; 6.57 score on a scale — p=0.025
N/A N=20 A Comparison of the Accurate Diagnosis of the Horizontal & Vertical Bitewing Images
Periodontal Diseases · Dental Caries
Primary: Caries Detection — 7.22; 6.48 teeth
Phase 1 N=47 First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection
Hepatitis B · Healthy
Primary: Incidence of Safety and Reactogenicity Events: Adverse Events — 1; 4; 2; 4 Participants